Ovid Therapeutics (OVID) may be one step closer to vindication with a rare disease treatment whose polarizing results led Wall Street to all but abandon the small drug company.
After a meeting with the Food and Drug Administration, Ovid is taking its therapy for the debilitating Angelman syndrome into a late-stage trial, one that will use the same definition of success employed in a prior study. The company said Thursday that the FDA agreed with its approach to determining whether Angelman patients are getting better. And that means Ovid could win FDA approval by replicating what it saw in an earlier trial.
About the Author Reprints
